FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a linker of formula (I) or a pharmaceutically acceptable salt thereof, a linker-drug conjugate of formula (II) or a pharmaceutically acceptable salt thereof, a linker-drug conjugate such as an antibody-drug conjugate of formula (III) or (IV) or a pharmaceutically acceptable salt thereof, as well as a pharmaceutical composition including such a binding unit-drug conjugate, and its use for the treatment of cancer.
EFFECT: obtaining sulfomaleimide-based linkers and corresponding conjugates.
19 cl, 28 dwg, 15 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ENGINEERED MULTI-SPECIFIC ANTIBODIES AND OTHER MULTIMERIC PROTEINS WITH ASYMMETRIC MUTATIONS IN THE CH2-CH3 REGION | 2018 |
|
RU2804031C2 |
| POLYPEPTIDE LINKER FOR PRODUCTION OF MULTI-SPECIFIC ANTIBODIES | 2018 |
|
RU2776302C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| TETRAVALENT SYMMETRICAL BISPECIFIC ANTIBODIES | 2019 |
|
RU2807346C2 |
| BISPECIFIC ANTIBODY AND USE THEREOF | 2021 |
|
RU2839153C2 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
